Zhang Rui, Lin Peng, Yang Hong, He Yun, Dang Yi-Wu, Feng Zhen-Bo, Chen Gang
Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. China.
Department of Ultrasonography, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P. R. China.
Oncotarget. 2017 Nov 26;8(65):108333-108354. doi: 10.18632/oncotarget.22659. eCollection 2017 Dec 12.
To investigate the clinical role and biological function of cyclin-dependent kinase 5 (CDK5) in hepatocellular carcinoma (HCC), 412 surgically resected tissue samples (HCC, n=171; non-HCC=241) were obtained and analyzed with immunohistochemistry. The diagnostic and prognostic values of CDK5 expression levels in HCC were clarified. Moreover, RNA-seq data or microarray datasets from The Cancer Genome Atlas (TCGA) (HCC, n=374; normal, n=50) or other public databases (HCC, n=1864; non-tumor=1995) regarding CDK5 in HCC were extracted and examined. Several bioinformatic methods were performed to identify CDK5-regulated pathways. experiments were adopted to measure proliferation and apoptosis in HCC cells after CDK5 mRNA was inhibited in the HCC cell lines HepG2 and HepB3. Based on immunohistochemistry, CDK5 expression levels were notably increased in HCC tissues (n=171) compared with normal (n=33, <0.001), cirrhosis (n=37, <0.001), and adjacent non-cancerous liver (n=171, <0.001) tissues. The up-regulation of CDK5 was associated with higher differentiation (<0.001), metastasis (<0.001), advanced clinical TNM stages (<0.001), portal vein tumor embolus (=0.003) and vascular invasion (=0.004). Additionally, TCGA data analysis also revealed significantly increased CDK5 expression in HCC compared with non-cancerous hepatic tissues (<0.001). The pooled standard mean deviation (SMD) based on 36 included datasets (HCC, n=2238; non-cancerous, n=2045) indicated that CDK5 was up-regulated in HCC (SMD=1.23, 95% CI: 1.00-1.45, <0.001). The area under the curve (AUC) of the summary receiver operating characteristic (SROC) curve was 0.88. Furthermore, CDK5 knock-down inhibited proliferation and promoted apoptosis. In conclusion, CDK5 plays an essential role in the initiation and progression of HCC, most likely via accelerating proliferation and suppressing apoptosis in HCC cells by regulating the cell cycle and DNA replication pathways.
为了研究细胞周期蛋白依赖性激酶5(CDK5)在肝细胞癌(HCC)中的临床作用和生物学功能,获取了412份手术切除的组织样本(HCC,n = 171;非HCC = 241),并采用免疫组织化学进行分析。明确了CDK5表达水平在HCC中的诊断和预后价值。此外,从癌症基因组图谱(TCGA)(HCC,n = 374;正常,n = 50)或其他公共数据库(HCC,n = 1864;非肿瘤 = 1995)中提取并检查了关于HCC中CDK5的RNA测序数据或微阵列数据集。采用多种生物信息学方法来识别CDK5调控的通路。在肝癌细胞系HepG2和HepB3中抑制CDK5 mRNA后,采用实验来检测肝癌细胞的增殖和凋亡。基于免疫组织化学,与正常组织(n = 33,<0.001)、肝硬化组织(n = 37,<0.001)和癌旁非癌肝组织(n = 171,<0.001)相比,HCC组织(n = 171)中CDK5表达水平显著升高。CDK5的上调与更高的分化程度(<0.001)、转移(<0.001)、临床TNM分期进展(<0.001)、门静脉癌栓(=0.003)和血管侵犯(=0.004)相关。此外,TCGA数据分析还显示,与非癌肝组织相比,HCC中CDK5表达显著增加(<0.001)。基于36个纳入数据集(HCC,n = 2238;非癌,n = 2045)的合并标准平均差(SMD)表明,HCC中CDK5上调(SMD = 1.23,95%CI:1.00 - 及1.45,<0.001)。汇总接受者操作特征(SROC)曲线的曲线下面积(AUC)为0.88。此外,敲低CDK5可抑制增殖并促进凋亡。总之,CDK5在HCC的发生和发展中起重要作用,很可能是通过调节细胞周期和DNA复制通路来加速HCC细胞的增殖并抑制其凋亡。